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Big Tobacco and the human genome: driving the scientific 
bandwagon? 
HELEN M. WALLACE1 
Abstract 
The tobacco industry first began to promote the idea that a minority of smokers are 
‘genetically predisposed’ to lung cancer in the 1950s. We used tobacco industry 
documents available as a result of litigation to investigate the role of the tobacco 
industry in funding the ‘scientific bandwagon’ described by Fujimura, in which 
genetics has come to dominate the cancer research agenda. From 1990-1995 inclusive, 
52% of the project funding allocated by British American Tobacco’s Scientific 
Research Group went to genetic research, mainly based in universities and at one 
cancer charity. The largest project involved a pharmacogenetic research unit, based in 
a UK medical school, which was established with the help of tobacco industry PR 
consultants in 1988. The unit received half its project funding from the industry in 
1992. Its main aim was to identify a minority of smokers who are supposedly 
‘genetically susceptible’ to lung cancer, so that smoking cessation measures could be 
targeted at them. This aim was adopted and promoted by influential scientists at the 
US National Institutes of Health and the UK Medical Research Council in the late 
1980s, in the run up to the Human Genome Project. 
BAT’s research funds were also used to counter claims by others to have identified a 
unique ‘genetic fingerprint’ for tobacco smoke in lung cancer cells. We conclude that 
the tobacco industry has played a significant role in shaping research agendas, in 
particular, by promoting the idea that individual genome screening would be of 
benefit to public health.  
Introduction 
Tobacco smoking was responsible for an estimated 3 million deaths worldwide in 
1990, predicted to rise to 10 million by 2030 if present trends continue.2,3 The 
tobacco industry has a long history of funding research into the health effects of 
tobacco as part of a sophisticated legal and public relations strategy.4,5 Its stra




 6,7,8,9,10 but we are not aware of any detailed examinations of its funding of
human genetic research.  
 
Fujimura (1988) describes a “scientific bandwagon”, which “exists when large 
numbers of people, laboratories and organizations commit their resources to one 
approach to a problem”.11 She describes how, by 1984, molecular biological cancer 
research became a line of research that scientists increasingly joined in order to build 
successful careers. The bandwagon was driven by major investments in infrastructure 
and very large increases in funding allocations, particularly from the US National 
Institutes of Health (NIH).  
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However, the NIH were not the first or only funders active in this area. From 1954 to 
1999 the Council for Tobacco Research (the CTR, formerly the Tobacco Industry 
Research Committee) was the main tobacco-industry-funded research body world-
wide, and genetics played a central role in its $20 million a year research 
programme.12 By 1994, the CTR was one of the largest private funders of medical 
research in the USA and had awarded nearly $225 million to approximately 1,000 
researchers, sponsoring “pioneering work in identifying familial cancers, the role of 
genetic factors in cancer formation, and the identification of oncogenes”. Its first 
director, Clarence Cook Little, was a eugenicist who promoted the idea that there 
might be a gene that both leads people to smoke and predisposes them toward cancer, 
implying that the statistical link between smoking and lung cancer was not causal.13 
To support his position, Little used a 1957 paper by the British statistician and 
eugenicist Sir Ronald Fisher, published in the British Medical Journal.14 In 1958, 
following a letter from Fisher to Nature,15 the New York Times reported that Fisher 
was a “consultant statistician to the tobacco manufacturers”.16  
 
Although Fisher’s theory no longer commands scientific support,17 genetic 
predisposition to lung cancer is still a topic of active research. It is possible that such 
research may help to elucidate the molecular mechanisms underlying cancer. 
However, some researchers have also claimed that genetic screening will one day 
predict which smokers will get lung cancer, allowing smoking cessation measures to 
be targeted at this minority of individuals. Claims to have developed a genetic test 
which “apparently distinguishes cigarette smokers whose genes make them prone to 
lung cancer from those resistant to developing the malignant tumour” were first made 
in the New York Times in 1973,18,19 by researchers who were seeking (and 
subsequently received) funding from the CTR.20,21 
 
However, this hypothesis is not supported by twin studies, which suggest that lung 
cancer has no significant inherited genetic component and that therefore there is no 
possibility of a genetic screening test with high clinical utility.22,23,24 Further, because 
many diseases are caused by smoking,25,26 all smokers benefit from quitting, 
whatever genetic variants they have. Genetic testing in clinical practice would 
therefore provide no additional useful information for physicians and could mislead 
individuals about the ris 27k of smoking.   
 
Hall et al. (2002) argue that the tobacco industry may have an interest in using the 
possibility of genetic screening for disease susceptibility to convince ambivalent 
smokers that they do not need to quit.28 This theory is consistent with a 1996 memo 
from the director of media at PR firm Burson-Marstellar to Philip Morris, which puts 
the marketing case for the tobacco industry to undertake this type of research:   
 
“A simple test might eventually be devised to tell a smoker whether 
or not he is at risk. This would put the burden of any consequence 
from smoking on the individual, and would clear the way for the 
non-susceptible population to smoke with a clear conscience”.29  
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Although the CTR ceased to exist in 1999, British American Tobacco (BAT) 
continued to fund academic research via its Scientific Research Group (SRG), 
including research on genetic predisposition to disease, until at least 2000.30 We 
therefore set out to detail the role of the SRG in human genetic research, using BAT 
documents released as a result of litigation, supplemented with related documents 
released by the CTR and by Philip Morris. We aimed to identify what research had 
been funded and why, and the influence of the tobacco industry on the research 
agenda.  
 
Whilst the tobacco industry may see promotion of genetic screening of smokers as 
advantageous to its business, it may perceive other genetic health research as a threat. 
In 1990, researchers began to link the pattern of damage in the p53 gene in lung 
cancer cells with benzo[a]pyrene, a constituent of tobacco smoke, and by 1996 
Denissenko and colleagues had demonstrated an in-vitro effect.31,32,33 The prospect of 
a unique ‘genetic fingerprint’ for tobacco smoke in lung cancer cells has implications 
for the financial liability of the tobacco industry. Bitten et al. (2005) investigated the 
tobacco industry’s response, showing that the industry conducted research which 
appeared to cast doubt on these findings.34 Our research, which overlaps with theirs, 
also sheds some further light on these developments. 
Methods 
Our primary sources were documents made publicly available as a result of past 
litigation settlements. In 2001, we visited the BAT depository at Guildford to identify 
the scientific research projects funded by BAT’s Scientific Research Group (SRG) 
during the 1990s. We used the search terms: “Scientific Research Group”; “SRG”; the 
names of the BAT employees responsible for the SRG (“Proctor” and “Boyse”); and, 
in secondary searches, the names of researchers and consultants funded by the SRG. 
We collected more than 800 documents in total during 10 days at the repository, 
including SRG meeting minutes, contracts, newsletters and notes of visits; grant 
proposals, reviewers comments and progress reports; BAT memos, notes and letters; 
and letters to BAT.  
 
The document set is not comprehensive due to limitations in both the supply of 
documents and their indexing, and the difficult logistics of obtaining access to the 
documents at Guildford.35,36,37 Making an exact catalogue of documents proved 
difficult, as documents with different Bates Numbers are sometimes copies of the 
same original and in some cases the distinction between single and multiple 
documents may be somewhat arbitrary. However, the SRG budgets we identified 
contain partial information for 1989, complete figures for 1990-1995 and projected 
figures for 1995-1997, allowing us to make an analysis of BAT’s research funding 
priorities from 1990-1995 (see supplementary material, S1). 
 
To obtain a fuller picture we conducted additional searches of two further tobacco 
industry websites using the names of researchers and consultants: the Council for 
Tobacco Research USA, Inc. (the CTR)38 and Philip Morris (PM).39 We omitted 
researchers and consultants primarily involved in nicotine research or environmental 
tobacco smoke (ETS). Our search terms and a summary of the additional documents 
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we identified are given in Table 1. The presence of documents in the CTR and PM 
files does not necessarily indicate a link between the company and the named 
researcher. For example, documents may include copies of published papers; 
newspaper articles; notes on conference presentations; or research proposals that have 
been refused.  
 
Table 1: Summary of CTR and PM documents*. 
Search term Number of CTR 
documents 
Number of Philip 
Morris documents 
Idle JR 460 304 
Daly AK 20† 8‡ 
Rothschild H 194 196 
Springall A 1 467 
Carter ND None None 
Cooper DN 4 13 
Currie G 1 5 
Poulsen H None 1 
Clausen J None 9 
Stell PM 11 21 
Field JK None 13 
Farmer P None 47 
Parry J None 83 
Feinstein A 108 1384 
* Documents relating to different individuals with the same name have been identified and 
omitted from these totals. Documents with different Bates Numbers are counted as distinct, 
even if they are copies of the same original. In some cases PM documents are copies of CTR 
documents. 
† All but 2 overlap with Idle JR. 
‡ All but 3 overlap with Idle JR 
 
By checking funding applications and their response, we established that two 
researchers (Idle and Rothschild) had received research funding from the CTR. A 
detailed analysis of these documents is included in this paper. Idle also received 
funding from Philip Morris, mainly for work on ETS which is largely omitted from 
this paper. The consultants J. Parry and A. Feinstein received funding from Philip 
Morris and from the CTR respectively. We used these documents to establish the 
extent of their tobacco industry links, but did not examine these projects in detail. 
Springall was a commercial consultant to BAT (not an academic researcher) so we did 
not investigate the PM documents listed in his name. 
 
We then searched PubMed40 for journal articles published by the researchers listed in 
Table 1 (omitting the consultants Feinstein and Parry). We used the documents to 
provide an overview of the SRG’s aims, objectives and relationships with researchers 
and consultants; to quantify the cost and duration of each research project and the 
importance of genetics in the programme; and to examine funding declarations on 
journal articles. We also produced two detailed chronologies of the involvement of 
BAT-funded researchers in research on ‘genetic susceptibility’ to lung cancer and one 
on p53 mutations in lung cancer cells (see supplementary material, S2, S3 and S4), 
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and analysed the role of these researchers in the development of the scientific 
bandwagon described by Fujimura. 
Results 
The SRG – aims and objectives 
BAT’s Scientific Research Group (SRG) was formed in 1986.41 A key objective was: 
“To maintain a detailed awareness of, and an ability to respond to, scientifically 
related regulatory issues that impact on cigarette use”.42 Research proposals were 
assessed by BAT not only for their scientific merit, but also for their contribution to 
the agreed strategic objectives of the BAT group. Future strategies for research were 
developed as issues arose and in 1993 gave particular emphasis to seeking 
“confounding factors” in the associations between both active and passive smoking 
and lung cancer and heart disease.43 The SRG considered “genetic predisposition” to 
be one possible confounding factor, along with other factors such as diet.  
Contracts 
BAT funded both consultants and researchers via the SRG. Researchers signed 
contracts with the British-American Tobacco Company Limited.44 These contracts 
allowed them to publish at the sole discretion of themselves and their research 
institutes, but required them to send copies to BAT at least 28 days in advance. BAT 
reserved the right to terminate grants at any time if the research programme did not 
follow the proposal.  
 
The consultants reviewed research proposals for the SRG. Although most were 
medical researchers based in universities, they signed contracts with BAT which 
committed them to safeguarding the “best interests of the Company”.45 In 1993, 
BAT’s consultants on molecular biology and epidemiology respectively were 
Professor James Parry (University of Wales, Swansea) and Professor Alvan R. 
Feinstein (Yale).46,47 Feinstein had a long history of involvement with tobacco 
industry research, including funding for “special projects” determined by tobacco 
industry lawyers.48,49,50,51 Parry, who was receiving project funding from Philip 
Morris in 1998, was described as having a “long-standing relationship” with the 
company, and had recently applied for a new grant.52 Both Parry and Feinstein were 
editors-in-chief of academic journals whilst employed as BAT consultants.  
The SRG - funding priorities and journal publications 
The SRG budgets we obtained were complete for the period 1990-1995, as detailed in 
the supplementary material, S1. Most of the SRG’s research budget during this period 
(60% or £1,570,600) was spent on projects based in UK universities and associated 
hospitals or research institutes, including one cancer charity. The remainder was spent 
on projects undertaken in overseas universities (26%) or by UK consultants (13%).  
 
Whilst research on nicotine (24% of funding) and ETS (12% of funding) were clearly 
of high importance to BAT, genetic research, mainly into cancer, was more important 
- receiving 52% of the total £2.6 million allocated for 1990-1995.  
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Table 2 outlines the genetic research projects funded by the SRG for the period 1990-
1995. Where indicated, projects extended before or after this six-year period, 
receiving additional funding. We have divided this genetic research broadly into two 
types:  
(i) research into whether some people are more genetically susceptible (or 
“predisposed”) to some diseases – particularly lung cancer - than others;  
(ii) research into the genetic damage caused by tobacco smoke and other factors, and 
the molecular mechanisms leading to cancer.  
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Journal publications 
Table 2 also shows the publications acknowledging BAT funding relating to each 
project. 
 
The largest number of journal papers resulted from the project led initially by 
Professor Jeffrey Idle at the University of Newcastle upon Tyne, UK. Of the 16 
papers by his research team listed in Table 2, six also acknowledge CTR funding and 
two acknowledge both the CTR and the Smokeless Tobacco Research Council 
(STRC, another tobacco-industry-funded body). Six additional papers79,80,81,82,83,84 
acknowledge support from the CTR and another three acknowledge the STRC.85,86,87 
Fourteen of these 25 tobacco-funded papers (12 with Idle’s name on) were published 
in Pharmacogenetics. editor-in-chief  from 1991 to 
October 1998,
Idle was of Pharmacogenetics
88,89 a journal which he founded whilst receiving BAT funding.  
 
For most of the projects we were unable to identify any journal papers acknowledging 
BAT funding. 
Projects 
Genetic susceptibility to lung cancer 
Research on genetic susceptibility to lung cancer received the most funding, 
confirming the tobacco industry’s continued interest in this area of research. Jeffrey 
Idle’s project was also the only project simultaneously funded by the CTR.90 
Chronologies for the projects involving Idle, Daly, Rothschild and Springall are 
provided in the supplementary material S1 and S2. 
 
Idle informed the CTR in 198691 that his 1984 Nature paper on role of the CYP2D6 
gene in metabolism of the drug debrisoquine and its link to risk of lung cancer “may 
herald a long-overdue change in the practice of epidemiology” and that he had 
established collaboration with the US National Institutes of Health (NIH) to pursue 
“the host factors which determine individual lung cancer risk”. He joined the CTR’s 
Scientific Advisory Board (SAB)92 in July 1986. Statements to the press by the NIH 
in 1987, endorsing Idle’s results and suggesting that genetic testing would allow 
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smoking cessation to be targeted at a minority of smokers, were regarded as 
“favorable publicity” by the industry.93,94 This led to a presentation by Idle to the 
CTR Board (which included representatives of six tobacco companies, two legal firms








Within a month, CTR and BAT public relations advisors became involved in helping 
him establish a “Laboratory of Cancer Pharmacogenetics” in the UK.97 The 
Pharmacogenetics Unit in the University of Newcastle Medical School, was “greatly 
expanded and revamped” to create a Chair for Idle. BAT’s chairman, Patrick Sheehy, 
was kept informed of progress.98,99,100,101 The university received a five-year 
“research agreement” from BAT on Idle’s move there in September 1988. n 1992102 I
50% of the project funding for “this and related research” at the unit was from the 
tobacco industry,103 which spent US$1.5 million on research projects there from 1989 
to 1996 (Table 3). The unit also received substantive funding from the North of 
England Cancer Research Campaign, the UK Medical Research Council (MRC)
the pharmaceutical company Bay
 
Table 3: Tobacco-funded projects in the Pharmacogenetics Unit, University of 
Newcastle Upon Tyne 
Dates Project  Funds Funder Researchers 
1989-1990 A case/control study of 
breast and lung cancer with 
the addendum of the 
debrisoquine study* 
US$77,700104,105 CTR JR Idle 




BAT JR Idle,  
AK Daly 
1991-1994 Pharmacogenetic 
epidemiology of lung 
cancer 
US$296,500108 CTR JR Idle,  
AK Daly 
1991-1994 Pharmacogenetics of 
nicotine metabolism 
US$318,700109 STRC‡ JR Idle,  
S Cholerton 
* Idle’s collaboration with Professor Henry Lynch (Omaha, USA).110 The first payment of 
US$47,000 was made prior to Idle’s move to Newcastle and is not included in the table. 
† Source: SRG budget documents. Two 3-year projects were funded. 
‡The Smokeless Tobacco Research Council (STRC), another tobacco-industry-funded 
body.111 
 
BAT’s commitment to fund Idle’s project was made on 7 April 1988,112 some days 
before his project was formally approved by the SRG113 and several months before 
his research proposal114 received an extremely critical review from Feinstein: a 
review which questioned his understanding of statistics.  115 The funding decisio
influenced by a meeting with the leading molecular biologist (now a Nobel Laureate) 
Dr Sydney Brenner, then director of the MRC’s Laboratory of Molecular Biology 
(LMB) in Cambridge. BAT report that Brenner:  
n was 
 
“went so far as to recommend the industry should carry out 
screening, if appropriate, for those individuals carrying genetic 
markers for diseases such as lung cancer”.116  
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The tobacco industry’s main aim in funding projects like Idle’s was to identify a 
“genetically susceptible” minority of smokers so that smoking cessation efforts could 
be targeted at them and “the rest of the population can be allowed to puff away 
contentedly and without serious risk”. 117 
 
BAT met Brenner on 30 March 1988. By the end of April he was a founding member 
of the Human Genome Organisation (HUGO), an organization that he is credited with 
first proposing.118 At the time, Brenner was also a member of the Council of the 
MRC.119 According to the Wellcome Trust, it was Brenner who gained the personal 
support of the then prime minister, Margaret Thatcher, after Brenner and Sir Walter 
Bodmer (a former student of Ronald Fisher) initially had difficulty persuading 
influential bodies in the UK to ‘think big’ about the genome.120 In 1986, Brenner had 
been told that any human genome mapping had to be undertaken within the MRC’s 
existing budget, but after gaining the prime minister’s support, the MRC was awarded 
an extra £11 million over three years, agreed in February 1989 and paid from the start 
of the 1989/90 financial year.121 There is no suggestion that Brenner was receiving 
funding from the tobacco industry in March 1988. However, BAT’s memo of the 
meeting notes that he “seemed quite willing to meet with BAT again on a specific 
subject”.   
 
A conference abstract by NIH researchers, sent “in confidence” by Idle to BAT, also 
appears to have influenced BAT’s decision to fund his research.122,123 The CTR’s 
response to a 1989 New York Times article advocating genetic screening of 
smokers124 was ecstatic, describing the NIH’s statements as “vindication” of it
research strategy,
s 





125 and interest from the NIH prompted the CTR to invite Idle to 
resubmit one of his research proposals126 and to make an extra payment t 127,128
 
Beginning in 1988, a series of studies failed to confirm Idle’s hypothesis of a link 
between CYP2D6 polymorphisms and lung cancer.129,130,131,132,133 CTR-funded 
studies in Norway and Los Angeles also failed to confirm the association and both
were ultimately published (in 1994 and in 1997). However, prior to the publication o
the Los Angeles results, Idle co-authored a series of reviews134,135,136,137,138 and
conference papers139 implying that genetic susceptibility to lung cancer had been 
firmly established.  
 
One review was published in Pharmacogenetics when Idle was already aware that the
preliminary results from Norway did not confirm the proposed association140. A 
response (also in Pharmacogenetics, but not published until two years later) 
concludes that the review is “factually misleading and gives an incorrect impression 
of …the current conclusions which can be drawn from the literature”.141 Genetic 
variations in CYP2D6 are now thought to play little or no role in lung 
cancer.142,143,144,145 
 
Henry Rothschild (University of Louisiana) was funded by the CTR from 1977.146,147 
In 1982, Rothschild gave evidence on behalf of the tobacco industry to the Waxman 
Hearings, which were considering proposals for new stronger warning labels on US 
cigarette packs. The industry argued that: “Science…would be frozen in its tracks if 
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Congress, through such legislation, tries to settle unresolved medical and scientific 
controversies.” Rothschild gave evidence that genetics may determine who gets lung 
cancer.148 The following month, on the advice of tobacco-industry lawyers,149 he was 
awarded a new ‘Special Project’ grant by the CTR to study genetic factors in lung 
cancer in Louisiana families.150 Rothschild received US$160,700 in total from the 
CTR for research on genetic factors in lung cancer.151,152,153,154 He co-authored three 
papers during this time that claim to support the concept of genetic susceptibility to 
lung cancer (none acknowledge tobacco industry funding).155,156,157,158 
 
In 1990 the Journal of the National Cancer Institute (JNCI) published two articles on 
genetic susceptibility to lung cancer – one by NCI researchers159 and one by Sellers et 
al.,160 on which Rothschild is a co-author and CTR funding is acknowledged. BAT 
describe the NCI researchers as “close to” Idle’s group.161 The papers gained 
extensive press coverage,162,163,164 some of which led to scientific criticism of the 
researchers for implying that genetics rather than smoking determines whether lung 
cancer develops.165 
 
Following the publicity surrounding the Sellers et al. (1990) paper, this research 
group published two further related papers which acknowledge CTR funding166,167 
and three which do not.168,169,170 
 (purchased by BAT f
£25,000
Springall’s BAT-funded project sought to confirm
the Sellers et al. findings, using the Louisiana data set
 
or 
171). In 1993, Springall reported that he had successfully reproduced the 
segregation analysis172, following initial difficulties.173 
 
Rothschild’s colleague J.E. Bailey-Wilson presented his team’s proposal for a pilot 
study of lung cancer probands with at least two affected relatives to BAT in October 
1993174. The SRG minutes record that if the pilot study fails to identify any genetic 
markers, the team hopes to go on to a global screen of the genome, funded by the 
NIH. BAT subsequently agreed to fund Rothschild’s genetic-linkage project “pending 
funding by the NIH”.175 We have been unable to identify any papers by Rothschild 
acknowledging BAT funding. Two NIH-funded papers by other authors also conclude 
that a major gene explains familial aggregation of lung cancer: both rely solely on 
Rothschild’s Louisiana data set.176,177 
   
In 2000, Rothschild was awarded three grants 
by the NIH, totalling more than US$660,000, to continue his research.178
 
In 2004, Bailey-Wilson et al. published a paper identifying a major lung cancer 
susceptibility locus in 771 families with three or more first-degree relatives affected 
with lung cancer.179 Press reports again claimed that the study paved the way for a 
genetic screening test to identify susceptible smokers.180,181,182 The paper appears to 
report the next step in the pilot project presented to BAT by Bailey-Wilson in 1993, 
and subsequently funded via a grant to Rothschild “pending funding by the NIH”, as 
described above. Rothschild is a co-author on the paper.  A subsequent paper, on 
which Bailey-Wilson and Rothschild are co-authors, investigates a different locus, 
again with funding from the NIH as part of the Genetic Epidemiology of Lung Cancer 
Consortium.183 The paper claims that evidence of a genetic basis for susceptibility to 
lung cancer has been demonstrated through genome-wide association studies (citing 
three new studies184,185,186) and via the segregation analyses previously reported by 
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the group in Sellers et al. (1990) and subsequent papers. It reports a further genome-





BAT supported a basic research programme on the p53 tumor suppressor gene at the 
Marie Curie Research Institute from 1987, led by its former director, Graham Currie. 
Currie’s colleague John Jenkins also worked on the project, which received £240,000 
over eight years to the end of 1993.187 Bitton et al. (2005) document how this 
relationship gave BAT an early insight into research on p53, which they felt could 
lead to either benefits or problems for the industry. 
 
One BAT-funded researcher, John Field, believed that research on p53 mutations had 
added weight to the link between smoking and lung cancer.188 The original lead 
researcher on his project, Philip Stell, had given evidence on the tobacco industry’s 
behalf in a smoking damages case in Finland in 1991189 but Field took on the project 
when Stell retired. In March 1994, BAT decided that further funding for Field’s 
project was “low priority” 190 and the SRG then noted: “Applications from other p53 
researchers will be sought.”191 
 
In contrast, a discussion forum by Krawczek and Cooper,192 published in Mutagenesis 
in 1998, uses an earlier paper, Krawczak et al. (1995)193, as the basis of a rebuttal of 
new evidence for a unique genetic fingerprint for tobacco smoke in p53 mutations in 
lung cancer cells. James Parry, editor in chief of Mutagenesis from 1986194 until 
November 2001195 was a BAT consultant in 1993
Bitton et al. (2005) note that no funding so
or competing interests were reported in the discussion forum, but find no evidenc
that either Cooper or Krawczak received tobacco funding for this research. However, 
we have identified additional evidence that the earlier 
196,197 and in 1998 was receiving 
project funding from Philip Morris.198 
Krawczak et. al.(1995) p
on which the forum was based, was BAT-funded: 
 Two of the authors (Cooper and Kakkar) received research funding from BAT 
(Kakkar from 1987-1992, for a project on arterial damage which we did not 
classify as ‘genetic research’ for the purposes of this investigation, see 
supplementary material S1; Cooper from 1992, as shown in Table 2).199 
 A BAT note of a visit to Cooper in June 1992200 and the minutes of two SRG 
meetings in 1993201,202 outline the proposed comparison reported in the paper. 
 A BAT note of a visit to Krawczak in Germany in September 1993 records that he 
is working with Cooper on a paper making this comparison and what they have 
found.203 
 A BAT memo from July 1994 refers to an enclosed “paper in press” from Cooper 
and cites part of the abstract.204 
 A BAT memo from March 1995 outlines new evidence linking mutations in the 
p53 gene to tobacco smoke and references Krawczak et al. (1995) as the basis of 
BAT’s rebuttal of the evidence.205 
 
Bitton et al. (2005) document how Parry again published a response in Mutagenesis 
when further evidence that smoking causes specific mutations to the p53 gene was 
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published, this time from an author based at a private institute sponsored by the 
German Association of Cigarette Manufacturers. When one of the authors of the 
original paper discovered Parry’s tobacco industry links, the journal’s publishers 
introduced a conflict of interest policy. Parry, who did not sign up to the arrangement, 
then left his role as Editor-in-Chief, and transferred to a non-executive role on the 
editorial board.206 
 
Poulsen, Clausen and Farmer’s projects investigated different types of DNA damage 
(oxidative damage and DNA adducts) in smokers and non-smokers. Poulsen’s 
research included attempts to try to reduce oxidative DNA damage in smokers by 
giving them dietary supplements.207 The efficacy of this approach is questionable208 
and beta-carotene supplements are now believed to increase risk of death in 
smokers.209,210,211 
Other issues 
We did not analyse the documents we collected which relate to environmental tobacco 
smoke (ETS). However, we found one example where genetic research was used to 
seek to undermine evidence of children’s exposure to ETS. In 1990 BAT’s consultant 
Feinstein published a commentary by Idle in the Journal of Clinical Epidemiology 
criticising work on ETS by Jarvis et al.212,213 In the article, which did not declare 
tobacco funding, Idle argued that genetic variations in
. 
 cotinine metabolism make 
cotinine tests an unreliable measure of tobacco smoke exposure Philip Morris had 
commissioned an outline of a review of cotinine from Idle in March 1989.
Idle copied his acceptance 
letter from Feinstein to BAT, saying: 
214,215 A 
faxed copy of his paper is in Philip Morris’ files, dated 4 July 1989,  a week before 
the Journal of Clinical Epidemiology recorded receiving it. 
216
 
 “Dear Ray, with the compliments of Professor Jeffrey Idle, Cotinine 
editorial now in press! (no changes asked for!) Regards Jeff.”217,218  
Discussion 
Our research has some limitations. We focused on the academic research funded by a 
single company (BAT) and restricted our analysis to projects involving human 
genetics. Our searches and the documents themselves may not be comprehensive, nor 
are recent documents generally available. However, our approach also has some 
strengths. Firstly, the SRG budgets we obtained are complete for the period 1990-
1995, enabling us to assess the relative importance of the different projects at this 
time. Secondly, searching the CTR and Philip Morris collections and PubMed for the 
names of the BAT consultants and researchers allowed us to build an in-depth picture 
of the history of the projects and related journal publications. Searching by name is 
one of the most effective strategies for identifying tobacco industry documents. 
 
The majority of SRG-funding in the period 1990-1995 was spent on human genetic 
research. The main area of research was genetic predisposition to lung cancer. 
Research was also used to counter potential threats to business (particularly the link 
between p53 mutation patterns and tobacco smoke) and to study ineffective 
alternatives to tobacco control (such as giving smokers vitamin supplements).  
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The tobacco industry selected research projects to suit its own strategic interests. 
Lawyers and public relations firms both played a role in influencing its research 
agenda. The industry’s influence did not lie in scientific fraud or suppression of 
results, but in providing significant support for those researchers who adopted its 
perspective. Idle, for example, remained sceptical that smoking causes lung cancer 
until at least 1999, when he endorsed Fisher’s theory in a letter to the Lancet.219 Vijay 
Kakkar, director of the Thrombosis Research Institute in London, where Cooper was 
based, reportedly informed the SRG in June 1992 that his hypothesis was that the 
most important risk factor for heart disease is not smoking, but levels of mercury in 
water. In addition, journal editors who were also receiving industry funding as 
consultants ‘placed’ editorials from seemingly independent scientists to support the 
industry’s position in matters of scientific controversy.  
 
The tobacco industry’s funding decisions played an important role in shaping the 
genetic research agenda, contributing to a scientific “race to find the gene or genes 
which predispose to lung cancer”.220 Idle, in particular, boasted of his connections 
with the NIH and was a member of the Lung Cancer Task Force at the US National 
Cancer Institute (NCI) from 1984, when the NIH began to increase massively its 
spending on cancer genetics research, creating the “scientific bandwagon” described 
by Fujimura (1988).  
 
Our research suggests that a coincidence of interests between advocates of molecular 
genetic research and the tobacco industry helped to drive this scientific bandwagon, as 
demonstrated by the timing of the meeting between BAT and Sydney Brenner. This 
meeting led to the establishment of Idle’s pharmacogenetics unit in 1988 - with 
funding from the tobacco industry, Bayer and the MRC - at a time when Brenner was 
anxious to convince the Thatcher government of the industrial applicability of human 
genome mapping. Brenner was not receiving funding from BAT at the time of the 
reported meeting. However, some years later, in 1996, the journal Science reported 
that a new ‘Molecular Sciences Institute’, based at La Jolla in the USA, for which 
Brenner had been recruited as director, was to receive a grant of $15 million a year for 
15 years from Philip Morris (a plan which appears to have been first discussed with 
Brenner in 1994221).222 Following this exposé, Brenner and Philip Morris terminated 
their research funding agreement for the institute.223 
 
The benefits to the tobacco industry of the promotion of gene screening for smokers 
are clear: it regarded the public endorsement of genetic screening by the NCI in press 
stories in 1987 and 1990 as “favorable publicity” and “vindication” of the research 
strategy that it had followed since the 1950s. Media stories about genetics are likely to 
exert a powerful public influence224 and self-exempting beliefs, such as believing in 
genetic causes for lung cancer, are one strategy used by smokers to avoid facing the 
difficulties involved in quitting smoking.225 Combined with the Thatcher 
government’s reluctance to strengthen tobacco control measures, it seems likely that 
the promotion of this ‘scientific solution’ to the problem of lung cancer both benefited 
the industry and harmed public health. 
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The main advantages for the scientific proponents of molecular genetics were: the 
opportunity to claim that their research could have a major impact on the incidence of 
cancer, rather than being restricted to studying biological mechanisms and rare 
familial diseases; and the chance to gain support from industry. This was particularly 
important as they sought to win public and political support (including financing) for 
human genome mapping in both the UK and the USA (where the Human Genome 
Initiative was launched in 1991). 
 
The difficulties in replicating genetic association studies are now well known226 and 
we found no evidence of scientific fraud. However, we did find evidence of 
interpretative bias (particularly “rescue bias”227) as contradictory evidence was 
discounted or ignored. Early studies tended to over-estimate genetic risk and in some 
cases expression of the relevant enzyme in the lung is very low228,229 or non-
existent,230 making a role in lung cancer unlikely. In the case of Idle’s research, this 
situation was exacerbated by ‘self-publication’ in a journal which he edited and 
founded, and his poor grasp of statistical method.  
 
Rothschild’s group also drew erroneous conclusions, probably as a result of sloppy 
science, rather than an intention to mislead. Familial aggregation of disease does not 
necessarily imply a genetic component231 and segregation analysis is sensitive to the 
assumptions made, which may give rise to spurious evidence of Mendelian 
inheritance.232 
 
In general, researchers seem to have genuinely believed that they could benefit their 
own careers and at the same time find a ‘scientific solution’ to the lung cancer 
problem that would also benefit the industry. Thus Proctor (1995) reports that 
molecular epidemiologists were surprised when a 1994 NIH twin study found “little if 
any effect of inherited predisposition on development of lung cancer”. Earlier twin 
studies had also failed to identify an inherited component, but, in the excitement of 
the race to find the genes for lung cancer, it had simply been presumed that these 
studies were not large enough. Small differences in genetic risk could still exist, as 
could rare cases of familial lung cancer, but this does not mean that genetic screening 
can be used to ‘predict and prevent’ lung cancer in the general population.233,24 
 
The idea that genetic screening would be of benefit to smokers nevertheless persists in 
the scientific literature and in the media. In 2003, press reports based on a new 
scientific paper234,235 claimed that a genetic test would be developed within three to 
four years to “show which smokers face lung cancer death”.236,237,238,239,240 Searches
we conducted using the CTR website revealed that the study’s corresponding author 
and press spokesman, Professor Zvi Livneh, had a history of funding from the tobacco 





Although genetic population screening has not (yet) been implemented, the policy 
implications of our findings are significant. In 1995, Idle co-authored a paper in 
Pharmacogenetics which advocates genetic screening of whole populations, with data 
stored on individual patient SMART cards, and expert computer systems on every 
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doctor’s desk.248 This idea, and claims that this approach would be of benefit to 
public health, subsequently became widely advocated: most famously in a May 1999 
lecture given by the leader of the Human Genome Project at the NIH, Francis 
Collins,249 by the UK Prime Minister Tony Blair in 2002,250, and in a 2003 UK 
Government White Paper which set out a vision for genetics in the National Health 
Service.251 Yet, 20 years after BAT helped to establish the first university 
pharmacogenetics unit, there is still limited potential for the genetic variants 
identified (singly or in combination) to provide clinically useful prediction of eit
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Our findings highlight the need for policy-makers, academic institutions and charitie
to take greater care to avoid conflicts of interest and to set health research priorities 
that are in the public interest, not in the interests of tobacco companies. More broadly, 
other industries – including the food and pharmaceutical industries – may have 
interests in promoting human genome screening, as may governments wh
in
 
Our research suggests that the main danger lies in failure to scrutinise the exaggerated
promises that scientists make to both policy makers and the media in order to secur
funding, rather than in scientific fraud.259,260, 261 As Rose (1994) describes, fear of
cancer became a powerful motivator for science funding for the Human Genome 
Project, but this also involved a political commitment to looking for causes within the
human body (to the supposedly determining genetic code), rather than outsi
causes to be found within everyday life and people’s environments.262 The 
o
“Unrealistic expectations are dangerous as they lead to poor 
investment decisions, misplaced hope, and distorted priorities, and 
can distract us from acting on the knowled
 
 
We conclude that the tobacco industry has played a significant role in shaping 
research agendas: in particular, by promoting the idea that individual genome 
screening would be of benefit to public health. Commercial vested interests can create 
and drive scientific bandwagons by bankrolling research in scientific institutions, and
placing reviews and articles in scientific journals, thus attracting public funding and 
building political support. This may drain considerable resources fro
a
 
Our research suggests that transparency, whilst undoubtedly important, is not enough
to ensure that science is conducted in the public interest. Many of Idle’s papers, for
example, did declare his funding sources, apparently without limiting the tobacco
industry’s influence on the research agenda or reporting of that research, both in 
scientific journals and in the wider press. It seems likely that subsequent decisions by 
many funders, including the MRC, NIH and most major charities, to cease co-fundin
tobacco industry research has been more effective. From 1988-1994 only one UK 
            Genomics, Society and Policy 
            2009, Vol.5, No.1, pp.1-54 
 
 
_____________   
 
Genomics, Society and Policy, Vol.5, No.1 (2009) ISSN: 1746-5354 
© ESRC Genomics Network. 
 
16
medical school did not accept tobacco funding,264 and charities that jointly funded 
research described above included: the Wellcome Trust,
the 
ing has not 




research agendas based on false assumptions and misleading claims. 
 
e Joseph Rowntree Charitable Trust has enabled the author to complete this work. 
 
53,59 the North of England 
Cancer Research Campaign and the North of England Childrens’ Cancer Research 
Campaign, the American Cancer Society, the Norwegian Cancer Society and Stop 
Cancer (California).80, ,81 82 However, the decision to cease co-fund
 p
 
Our findings highlight how research funding mechanisms established by the T
and Reagan governments allowed vested interests to set research priorities in 
universities and public institutions and to encourage widespread publication, 
endorsement and reporting of spurious scientific findings. We recommend that, in 
addition to transparency, more democratic decisions about research funding pri
are required. This should include greater public accountability and scrutiny of 
research investment decisions, and active steps to prevent political ‘en
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Idle (at St Mary’s Hospital) co-authors paper on role of CYP2D6 in debrisoquine metabolism.1  
Jul 1980 Idle co-authors abstract suggesting CYP2D6 is linked to the risk of lung cancer in smokers.2 
Feb 1981 Idle co-authors paper on debrisoquine metabolism in Nigerian cancer patients.3 
11 Jun 
1981 
Notes from a talk by Idle in CTR files.4,5(The talk is published in 1982.6) 
8 Nov 
1984 
Idle co-authors Nature paper on genetic susceptibility to lung cancer.7  
 




Idle joins Cancer Research Advancement Board at the Irish Cancer Society.8  
1 July 
1986 
Idle joins the CTR’s Scientific Advisory Board (SAB).9 He informs CTR in his CV that his 
1984 Nature paper “may herald a long-overdue change in the practice of epidemiology” and that 
he has established collaboration with the NIH to pursue “the host factors which determine 
individual lung cancer risk.” 
3 Mar 
1987 
Idle presentation on nicotine metabolism to the SAB.10 
21 May 
1987 
“Genetics linked to lung cancer predisposition” press story, with Idle’s work endorsed by the 
NCI and by Dr Alfred Knudson (another SAB member).11 
18 Jun 
1987 
The CTR board discuss the “recent favorable publicity” relating to Idle and Knudson’s work12.   
11 Dec 
1987 
Idle presents his research at the CTR annual meeting.13  
Dec 1987 CTR approve a $47k grant to Prof Henry Lynch to collaborate with Idle14, as part of Lynch’s 
existing project. 15,16,17 
Dec 1987 Idle writes a research proposal for the “Establishment of a Laboratory of Cancer 
Pharmacogenetics”. 
Jan 1988 The CTR’s PR consultant sends Idle’s laboratory proposal to BAT’s PR consultant, asking for 
the names of UK companies that might back the plan.18 
5 Feb 
1988 
Idle interviewed by BBC about genetic susceptibility to cancer.19 
24 Feb 
1988 
SRG Chair informs BAT’s Chairman (Patrick Sheehy) that Idle “is Professor elect at a greatly 
extended and revamped department of Pharmacology at Newcastle University (where BAT also 
has connections) and I anticipate that through the Scientific Research Group we shall be 
supporting his work there”.20  
18 Mar 
1988 




BAT meet the molecular biologist Dr Sydney Brenner, who supports the idea of genetic 
screening for lung cancer susceptibility.23 
7 Apr 
1988 




The SRG meeting agrees to fund Idle.25 
21 Apr 
1988 
BAT’s consultant Roe comments on Idle’s proposal26 including a note on the historical 
background to tobacco industry’s interest in genetic susceptibility. 
1 Jun 1988 A lunch appointment is made for Idle to meet Sheehy on 25 July.27 
23 Jun 
1988 
Idle is a guest in the BAT tent at Wimbledon.28 Other guests include Sir Peter Froggatt, chair of 
the Independent Scientific Committee on Smoking and Health. 
2 Sep 
1988 
Idle’s research proposal to the SRG: “Molecular Epidemiology of Lung Cancer Risk”.29 
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BAT send a five year “research agreement” to the University of Newcastle.30 
Oct 1988 Idle becomes Professor of Pharmacogenetics at the University of Newcastle Upon Tyne, UK.31 
19 Dec 
1988 
Feinstein’s review of Idle’s BAT proposal severely criticises his epidemiology.32 
1988 Paper by Roots et al. suggests Idle’s proposed association (between debrisoquine metabolism 
and lung cancer) is either weak or does not exist.33 
1989 Idle is WHO Committee Chairman “Genetic predisposition to toxic effects of chemicals”.  
1 Jan 1989 BAT begins funding Idle’s project.34 
27 Mar 
1989 
CTR visits Lynch and express doubts about Idle’s part of his project.35 
Mar 1989 Daly joins Idle at Newcastle.36 
Mar/Apr1
989 
Idle paper reviewing his previous work on lung cancer susceptibility.37 
3 May 
1989 




Idle co-authors a paper linking genetic predisposition to lung cancer to debrisoquine 
metabolism39. Idle had sent the final manuscript to BAT in January with a note: “…Nowhere 
does it say that smoking causes lung cancer…”.40 
16 May 
1989 
New York Times article41 predicting that genetic tests for vulnerability to cancer will be 
available in 3 to 5 years. Quotes NCI researchers saying that genetic tests could help focus anti-
smoking efforts. 
June 1989 “VINDICATION” speech by a CTR employee, about the New York Times article and the views 
expressed by NCI42. Refers to Idle as one CTR researcher working on genetics and lung cancer. 
1 July 
1989 
Idle and NCI researchers publish a paper on susceptibility to lung cancer in workers exposed to 
occupational carcinogens, which advocates screening and targeting of susceptible individuals.43 
Jul/Aug 
1989 
Idle and NCI researchers publish a paper re-analysing the data from 1984 Nature paper and 
supporting its conclusions.44 
2 Aug 
1989 
CTR staff meeting notes that NCI “has indicated interest” in Idle’s research and that they have 
asked Idle to resubmit his application.45 
4 Oct 
1989 
Lynch requests $24,500 to extend Idle’s part of his CTR project (this is approved).46 
31 Oct 
1989 
Wall Street Journal article, quoting NCI advocating genetic testing for lung cancer.47 
4 Nov 
1989 
Idle publishes a Lancet commentary advocating his theory.48 
30 Nov 
1989 
Idle applies for a CTR grant.49,50 The proposal refers to an attached letter of collaboration from 
NCI. 
20 Dec  
1989 
Idle informs CTR that he has received a letter of collaboration from NCI and seeks an additional 
$20,000 for his research with Lynch.51 
4 Jan 1990 CTR agrees to pay the $20,000 requested by Idle.52 
5 Jan 1990 Idle writes to Glenn to thank him53:“We may now be on the road to lay some myths to rest!” 
March 
1990 
Idle’s CTR proposal receives mixed reviews.54,55,56,57 
17-20 
April 1990 
Idle’s CTR proposal is withdrawn (no reasons given). 
July 1990 Idle and his NCI co-author publish a paper defending the conclusions of their studies58 against 
new data that does not support their findings59,60. No funding acknowledgements. 
10 July 
1990 
Letter from Idle explaining that his chapter is missing from a recent WHO publication because 
the WHO objected to his view that there is “an uncomfortable credibility gap in the widely-held 
belief that cigarettes cause lung cancer…”.61 (Note: an unedited draft of this paper is in Philip 
Morris’ files, 21 Sep 1989).62 
17 July 
1990 
SRG visit Idle at Newcastle.63 
1 Aug 
1990 
The Journal of the National Cancer Institute (JNCI) publishes two articles on genetic 
susceptibility to lung cancer – one by NCI researchers64 and one by Sellers et al (who 
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acknowledge CTR funding).65 The editorial66 suggests that the two papers may have identified 
the effect of the same gene. 
BAT describe the NCI group as “close to” Idle’s group.67 
August 
1990 
The JNCI papers gain extensive press coverage.68,69,70 
6 Oct 
1990 
Letter from Idle and colleagues to the Lancet about developing tests of variations in the 
CYP2D6 gene71. No tobacco industry funding is acknowledged. 
15 Oct 
1990 
Letter to Idle from Stephanie London (University of California School of Medicine) agreeing to 
collaborate and send DNA samples.72 
18 Oct 
1990 
Idle writes to CTR seeking an additional £29,500 ($57,741) to begin work with London.73 
30 Oct 
1990 
CTR approves a supplemental grant of $57,741 to Idle via Lynch.74 
26 Nov 
1990 
Idle and Daly re-apply for a CTR research grant to include collaborations with London in Los 
Angeles and Dr Anne-Lise Børrensen in Norway.75 
Jan 1991 The authors of the 1990 JNCI papers are criticised for implying that genetics rather than 
smoking determines when lung cancer develops.76 
4 Mar 
1991 




Idle publishes a review of genetic susceptibility to cancer which criticises IARC for 
emphasising the role of tobacco in lung cancer and omitting the genetic constitution of the 
population78. No acknowledgement of tobacco-industry funding. 
Apr 1991 Idle and Daly’s project “Pharmacogenetic Epidemiology of Lung Cancer” is considered at the 
CTR’s SAB meeting and funded as requested.79 
1 Jul 1991 Idle and Daly’s CTR project begins. They receive $96,538 in year 1, $100,000 in year 2 and 
$99,959 in year 3.80 
8 Aug 
1991 
Letter from Daly to BAT seeking travel funds and saying the manuscript sent to them in March 
will now be published in the new journal Pharmacogenetics.81 
Oct 1991 The first edition of Pharmacogenetics is published. Idle is a founding editor and Editor-in-Chief 
(until October 1998)82,83. It includes the Daly et al. paper,84 which acknowledges part funding 
from BAT.  
15 Oct 
1991 
Idle resigns from the CTR’s SAB following a dispute about expenses.85,86 He continues to 
receive project funding.87 
Nov 1991 Idle co-authors a paper in Pharmacogenetics, finding a low frequency of ‘poor metabolisers’ in 
Turkey.88 No funding acknowledgements. 
4 Dec 
1991 
Idle and Daly’s renewal application for the second year of their CTR grant.89 Informs the CTR 
that their Norway study does not support Idle’s earlier findings. 
1991 Two further papers cast doubt on Idle’s findings.90,91 
1992 Daly and Idle’s progress report to BAT for 1991.92 
25 April 
1992 
Idle and Daly co-author a paper on genetic variations in CYP2D6 in patients with Parkinson’s 
disease.93 Acknowledges part funding from BAT. 
5-7 May 
1992 
BAT’s SRG minutes note the large number and complexity of metabolising enzymes and state: 
“it appears unlikely that a specific relative risk for individuals can be calculated”.94 
30 Nov 
1992 
Idle and Daly’s renewal application for the third year of their CTR grant95. Reports that the 
Norwegian part of their study has found no link between CYP2D6 polymorphisms and lung 
cancer, but argues there may have been recruitment problems which will not arise in the larger 
Los Angeles study. 
Nov 1992 New results from NCI researchers report only a weak association between CYP2D6 and lung 
cancer.96 
Dec 1992  Idle and 18 of his Newcastle colleagues publish a review of genetic susceptibilities to cancer in 
Pharmacogenetics.97 They criticise a recent study (Wolf et al., 199298) that found no link 
between CYP2D6 and lung cancer risk. Funding acknowledgements include BAT, the CTR and 
the STRC. 
1993 Idle becomes Chief Executive of Genotype Ltd99 as well as head of department and head of the 
School of Clinical Medical Science at Newcastle. He has raised £2 million in outside funding 
for the Pharmacogenetics Unit since 1988. 
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Mar 1993  
Daly, Idle and review genetic variations in metabolism, claiming that the majority of studies are 
confirming Idle’s findings.100 Funding from BAT, the CTR and the STRC is acknowledged. 
7-9 Jun 
1993 
The SRG reports that Idle and Daly are awaiting the results of the LA study; developing genetic 
tests for GSTM1 and CYP2E1 and have made a new research proposal.101 
Jul 1993 
 
Daly and Idle co-author a short paper identifying another genetic variation in CYP2D6102. BAT 
and CTR funding is acknowledged. 
Aug 1993 
 
Daly and Idle co-author a paper on the GSTM1 gene and bladder cancer.103 Funding from BAT 
and the CTR is acknowledged.  
Aug 1993 Idle and Daly’s revised application to BAT104 (includes CYP1A2, CYP2A6, CYP2D6, 
CYP2E1). Visit from SRG Chair (Thornton) to Idle and Daly.105 
Oct 1993  Idle, Daly and Newcastle co-workers publish a review of genetic susceptibility to cancer, stating 
CYP2D6, CYP1A1 and GSTM are recognised candidate genes and that data are beginning to 
emerge on CYP1A2 and CYP2E1106. Acknowledges BAT and CTR. 
20 Oct 
1993 
BAT agrees to fund the “Interindividual variation in nitrosamine metabolism” project, with 
Daly as lead investigator, from 1 January 1994 to 31 December 1996.107 
28-30 Oct 
1993 
SRG meeting.108 Notes that trying to identify whether some smokers who develop lung cancer 




Idle and Daly apply to CTR for a further three years’ of funding109,110, enclosing two letters of 
collaboration.111,112 
Jan 1994 Idle co-authors another review of genetic variations and drug metabolism, which also states that 
CYP2D6 has been shown to be associated with cancer risk.113 
1 Jan 1994 Idle co-authors a letter to the Lancet on the link between genetic variations in CYP2D6 and 
nicotine metabolism.114 Acknowledges funding from the STRC. 
Apr 1994  Idle, Daly and others at Newcastle publish a paper in Pharmacogenetics with their Norwegian 
collaborators, reporting no significant link between genetic variations in CYP2D6 and lung 
cancer .115 Acknowledges CTR funding. 
Apr 1994  Idle, Daly and colleagues at Newcastle publish another paper in Pharmacogenetics investigating 
whether newly discovered CYP2D6 mutations could explain discrepancies between genetic test 
results and debrisoquine metabolism.116 Acknowledges BAT funding. 
Apr 1994 Wolf et al.’s response to Idle et al.’s 1992 review is published in Pharmacogenetics (it was 
submitted in Jan 1993).117 They express concerns that Idle’s article is “factually misleading” 
and that his “strong opinions…are preventing proper, scientifically correct analysis of the 
available data”. Idle and others respond (no tobacco funding is acknowledged).118 
25 Apr 
1994 
CTR refuses Idle funding for his proposed further project.119 
Jun 1994  Idle and Daly co-author a paper in Pharmacogenetics120 reporting on the frequency of ‘poor 
metabolisers’ in Jordan. BAT funding acknowledged.  
7 Jul 1994 Idle and Daly’s final report to BAT.121 
Nov 1994 Daly, Idle co-author a review of metabolism genes and disease susceptibility.122 
Mar 1995 
 
Daly, Idle, London and others publish a new mutation in the CYP2D6 gene.123 Acknowledges 
funding from BAT and the CTR. 
Aug 1995 Idle and Daly co-author a paper in Pharmacogenetics, discussing how to improve the accuracy 
of CYP2D6 genetic testing.124 BAT funding acknowledged. 
Aug 1995 Idle and Daly co-author a paper in Pharmacogenetics on CYP2D6 and NNK activation (which 
concludes that this is not important)125. No funding acknowledgements. 
Aug 1995 London, Daly and Idle investigate lung cancer risk and genetic variations in GSTM1.126 They 
find no link with lung cancer risk overall, but suggest there might be a link for lighter smokers. 
CTR funding is acknowledged. 
16 Jun 
1995 
Idle and Gonzalez (co-editor of Pharmacogenetics) named as inventors on a US patent for 
CYP2C9 and CYP2A6 test kits (granted on 6 April 1999).127 The description claims that 
CYP2A6 is linked to lung cancer risk. 
Sep 1995 Idle co-authors a paper on genetic variations in CYP2A6 and suggests it is linked to both cancer 
susceptibility and nicotine metabolism.128 
Nov 1995  Daly publishes a paper reviewing drug metabolism, which admits that links between CYP2D6 
and lung cancer are controversial.129 
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Late 1995  Smith et al.130 publish a review of genetic variability and cancer susceptibility. They conclude 
that the role of CYP2D6 remains unclear and that the original strong associations have not been 
confirmed. 
Dec 1995 London, Idle and Daly co-author a paper which reports that CYP1A1 does not appear to affect 
lung cancer risk131. No tobacco industry funding is acknowledged. 
Dec 1995 Idle co-authors a paper which advocates genetic screening for drug metabolism.132 
Dec 1995 NCI researchers (in Pharmacogenetics) consider possible explanations for some studies finding 




Idle moves to the Norwegian University of Science and Technology in Trondheim.  
1 Jan 1996 BAT begins payments for Daly’s project on CYP1A2 and CYP2E1.134 
Apr 1996 London, Daly and Idle co-author a paper finding no link between CYP2E1 and lung cancer 
risk.135 Support from CTR acknowledged. 
Jun 1996  Idle (now at Trondheim) and co-workers at Newcastle publish a paper in Pharmacogenetics on 
CYP2D6 and smoking status, finding no link.136 Support from the STRC is acknowledged. 
19 Aug 
1996 
Idle and Daly co-author a paper describing an improved genetic test for CYP2D6. No tobacco 
funding acknowledged.137 
Aug 1996 Daly and Idle co-author a paper reporting improved detection of some genetic variations in 
CYP2D6 (in Pharmacogenetics).138 Acknowledges support from BAT and the CTR. 
Sep 1996 Daly, Idle and others review the methods of detection of mutations in CYP2D6.139 No funding 
acknowledgements. 
Dec 1996 London, Idle and Daly co-author a paper in Pharmacogenetics, finding no link between 
CYP2C9 and lung cancer risk.140 CTR acknowledged. 
Jan 1997 A meta-analysis of studies on CYP2D6 and lung cancer susceptibility is published.141 finding 
no association and concluding that “the quality of the studies left much to be desired”. 
Apr 1997 Idle and Daly are co-authors on a paper finding two new variants in CYP2D6.142(published in 
Pharmacogenetics). No tobacco funding acknowledged.  
Jun 1997 London, Daly, Idle and co-workers publish a paper on the CYP2D6 Los Angeles study.143 
Concludes that polymorphisms in CYP2D6 are not a strong risk factor for lung cancer. 
Acknowledges CTR. 
Sep 1997 Idle co-authors a paper on CYP2A6 metabolism.144 No funding acknowledgements. 
Oct 1997  Idle and former colleagues at Newcastle publish a paper in Pharmacogenetics on smoking 
behaviour and CYP2D6 genotype, concluding that it may influence ‘dependence’.145 
Acknowledges STRC. 
Oct 1997  London, Daly, Idle co-author a paper in Pharmacogenetics on lung cancer risk and CYP2C9.146 
They find no link. No tobacco funding acknowledged. 
Feb 1998 A paper by a French team finding no association between CYP2D6 and lung cancer 
susceptibility is published in Pharmacogenetic.147 
Mar 1998 NCI researchers conclude that CYP2D6 is not a marker for lung cancer risk but “the concept 
that genetic polymorphisms may contribute to differential cancer risk is sound”.148  
Apr 1998 Cholerton and co-workers at Newcastle publish a paper on the lack of association between a 
genetic variation in the DRD2 gene and cigarette smoking.149 They acknowledge part funding 
by BAT. 
Jun 1998 A meta-analysis of studies on CYP2D6 is published in Pharmacogenetics by a team at Sheffield 
University.150 They conclude that there may be a small difference in risk but “it is hard to 
justify further studies”. 
Jul 1998 Idle co-authors a paper on CYP2A6 metabolism151. Acknowledges support from Rothmans 
International Services Ltd and the United States Tobacco Company Ltd. 
Dec 1998  Idle, London, Daly co-author a paper in Pharmacogenetics, on the CYP2D6 Los Angeles 
study.152 It attempts to find a better correlation by including some rarer mutations (but does not 
succeed). Part funding from the CTR acknowledged. 
Dec 1998  Daly and co-authors publish a paper on genetic variations in CYP2E1 (they find none of 
functional significance).153 They acknowledge BAT funding. 
Dec 1998 Daly co-authors a paper which concludes that CYP2D6 studies have not been confirmed but 
that CYP1A1 and CYP2E1 are of possible functional significance.154 
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London (now at the US National Institute of Environmental Health), Idle, Daly and a co-author 
publish a paper in the Lancet on CYP2A6.155 They find no significant link with lung cancer risk 
or smoking habits. No tobacco funding acknowledged. 
12 Jun 
1999 
Idle (now based in the Czech Republic) letter to the Lancet saying he differs with his co-authors 
on the paper.43 
Mar 2000 A meta-analysis of studies of genetic variations in CYP1A1 and lung cancer risk is published in 
Pharmacogenetics, finding no link.156 
Jun 2002 Idle is a co-author on a paper finding that debrisoquine metabolism is influenced by CYP1A1 as 
well as CYP2D6 and proposing this as the reason for the discrepancies between studies.157 
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S3: Rothschild chronology 
 
1977-1981 Rothschild funded for CTR “Special Project 91”.1,2  Total funding: $121,821.3 
Feb 1982 CTR lawyers recommend a further $25,000 for Rothschild to look at “genetic aspects of lung 
cancer”.4 
Mar 1982 Rothschild gives evidence for the tobacco industry at the Waxman hearings, arguing that 
genetics may determine who gets lung cancer.5 
Apr 1982 Rothschild’s funding for CTR “Special Project #118” is approved.6 
7 Jun 1983 Rothschild receives approval for a further $34,359 to extend CTR Special Project #118.7 
Feb 1986 Rothschild co-authors a paper claiming to support the existence of “a susceptibility gene to 
lung cancer” .8 No funding acknowledgments. 
28 Aug 1986 CTR approves $48,764 further funding for Rothschild’s “Special Project #138”.9 
Oct 1986 Correction to Feb 1986 paper published.10 
1 Aug 1987 Rothschild co-authors another paper claiming to support the hypothesis of genetic 
susceptibility to lung cancer.11 Funding acknowledgments do not include the CTR. 
12 Jan 1988 CTR approves another $52,582 for Rothschild’s “Special Project No. 138-A”.12 
Nov/Dec 
1988 
Rothschild co-authors another paper suggesting lung cancer susceptibility may also increase 
risk of other cancers.13 CTR not included in funding acknowledgements. 
Aug 1990 Rothschild is a co-author on the JNCI paper Sellers et al.(1990), which gains extensive press 
coverage for supposedly identifying a genetic factor in lung cancer [see Idle chronology]. 
1991 BAT begin funding Springall to reproduce Sellers et al.’s results. Springall receives £72,700 
over three years.  
1 Jan 1992 Rothschild co-authors a paper which finds that family history of lung cancer does not appear 
to differ with cancer type.14 Part funding from CTR acknowledged. 
1 May 1992 Rothschild co-authors a further paper on evidence for an interaction between smoking and 
genetic predisposition to lung cancer.15 No funding acknowledgements. 
5-7 May 1992 The SRG minutes note that Springall and Lee have purchased Rothschild’s dataset (for 
£25,00016) 
  
but are having difficulty reproducing Sellers et al. and “are concerned his model 
may be the wrong one.”.17
Jul/Aug 1992 Rothschild is a co-author on another paper suggesting that “the genetic component of lung 
cancer may be greater than previously estimated”, although the paper concludes that it is 
premature to suggest genetic screening.18 No funding acknowledgements. 
April 1993 Rothschild is a co-author on another paper which claims to provide evidence that a genetic 
factor may affect the risk of lung cancer.19 Part funding from the CTR is acknowledged. 
7-9 June 1993 The SRG reports that Springall has successfully reproduced Sellers et al. and that a proposal 
has been submitted from the Sellers group to the SRG.20 
Oct 1993 Rothschild’s colleague JE Bailey-Wilson presents their proposal.21 Rothschild’s project then 
listed as a new project approved, under the name of another colleague: R Elston.22 
Jan 1994 SRG begin funding Rothschild and colleagues for a 3-year project on the genetics of lung 
cancer “pending funding by the NIH” (£118,000 in total).23  
Sept 1994 Rothschild co-authors another paper on genetic susceptibility to “smoking-associated 
cancers”.24 No tobacco funding acknowledged. 
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S4: Genetic damage chronology 
 
Date Notes 
1987 BAT begins funding Currie’s project on p53 and lung cancer at the Marie Curie Research 
Institute. The project receives £240,000 over 8 years to the end of 1993.1 
1990 The first paper suggesting a link between p53 mutations in lung cancer cells and tobacco 
smoke is published (Chiba et al, 1990).2 A copy in Philip Morris’ files contains the added 
handwritten comment “No association of p53 mutations and smoking”.3 
Sep 1991 BAT visit Graham Currie and John Jenkins at the Marie Curie Research Institute.4 
Undated 
(1991) 
Field and Stell’s research proposal to BAT5. They say that the p53 mutation pattern in lung 
cancer adds weight to the association between smoking and lung cancer. They plan to look at 
p53 mutations in head and neck cancers.6 
Oct 1991 Funding for Stell and Field’s project begins. 
Feb 1992 Field et al (1992).7 
1992 List of SRG research projects8 including brief summaries of Field and Currie’s projects on 
p53 and Clausen’s on adduct levels in smokers and non-smokers and the effect of dietary 
antioxidants.  
May 1992 SRG meeting.9 Notes p53 mutation spectra as an “important area”. Expresses doubts about 
Field but notes Jenkins’ advice is helpful. Notes that Clausen “has found the adduct levels of 
smokers and non-smokers to be comparable”. 
Jun 1992 SRG visit to the Thrombosis Research Institute in London.10 
“The SRG’s interest in Dr Cooper’s project stems from the possibility that mutations in 
protein C (leading to various forms of thrombosis) might be similar to those in mutated 
proteins associated with other diseases, on the basis that DNA is most likely to mutate at 
specific sites and not at random. The extent to which the spectrum of inherited mutations that 
arise in, for example, the p53 isolated from lung cancer cells is a matter of interest and would 
clearly have a bearing in assessing the importance of environmental chemicals in causing 
mutations.” 
BAT also meet Professor Kakkar, Director of the Unit. 
Jul 1992 Field(1992).11 
Aug 1992 BAT funding for David Cooper’s project begins. 
Aug 1992 Skaanild and Clausen (1992).12 No funding acknowledgements. 
Mar 1993 
 
Slingerland et al (1993).13 John Jenkins is a co-author. 
Emphasises the role of selection of p53 mutations during tumour progression. 
Acknowledges funding from the National Cancer Institute of Canada and the Medical 
Research Council of Canada. 
Apr 1993 BAT funding begins for Peter Farmer’s project comparing genetic damage in smokers and 
non-smokers.14  
May 1993 Field co-authors a paper which highlights the link p53 mutations and cigarette smoke.15 
May 1993 Spandidos et al(1993).16 Field is a co-author. 
Jun 1993 SRG meeting17. Although Cooper’s project is entitled “Mutations in thrombotic disease”, 
BAT notes: “Dr Cooper is comparing the types of mutations inherited in the germline with 
those found in p53 genes isolated from tumour tissue. The considerable similarities suggest 
that p53 mutation spectra are mainly dependent on the position and sequence of the DNA.” 
Aug 1993 Clausen, J (1993).18 
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BAT visit to Mohr and Krawczak in Germany.19 
Records that Ulrich Mohr has now accepted the invitation to become a consultant to the SRG. 
“Dr Krawczak works in collaboration with Dr DN Cooper (supported by BAT at the 
Thrombosis Research Unit). 
They are both interested in Human Genetics and met when both worked for Professor 
Schmitke in Gottingen. Professor Schmitke has now moved to Hannover. Krawczak and 
Cooper have shown, for example, the nucleotide sequence –C-G- is inherently unstable after 
methylation (which occurs naturally in vertebrates)…causing a G-A transition in the 
complementary strand. 
They have now compared mutations in p53 derived from somatic cells (i.e. cancer derived) 
with mutations in p53 derived from germ-line cells…88% homology is claimed, suggesting 
that most mutations in p53 in somatic cells are the result of genetic instability rather than 
being caused by environmental chemicals. Unfortunately the paper on this subject submitted 
to ‘Nature’ has been rejected out of hand, probably as too revolutionary. It will now be 
submitted to ‘Science’.” 
Oct 1993 Field is lead author on a review paper discussing p53 mutations in lung cancer and head and 
neck cancer.20 He again contradicts BAT’s position. 
Oct 1993 SRG meeting.21 The SRG discuss David Cooper’s research on “Mutational spectra of somatic 
disease”. “Dr Cooper compared somatic gene mutations from a database of tumour-derived 
p53, to his own database of inherited germline mutations which are thought to arise 
spontaneously rather than as a result of environmental factors. The distribution of mutation 
types was found to be similar in the two databases, although G to T transversions were more 
common in the tumour samples. Dr Cooper stated that the vast bulk of mutations are formed 
by endogenous processes, and that it is impossible to determine the cause of a single mutation 
in an individual.” 
Dec 1993 BAT’s RE Thornton writes a note for the Tobacco Strategy Group, summarising the SRG’s 
October meeting.22 
Thornton notes “Dr Cooper’s work, originally targeted at the genetic basis of thrombotic 
disorders had turned out to be widely applicable and relevant to a number of diseases. 
Specifically, he was now examining the applicability of his ideas on spontaneously occurring 
genetic mutations to cancer.” 
Feb 1994 Field applies for renewal of his SRG grant.23 
Mar 1994 The SRG decides that further funding for Field’s project is “low priority” .24 
Jun 1994 Tavares et al (1994).25 Farmer is a co-author. 
 “The [adduct] concentrations in the newborns from smoking mothers…was significantly 
higher…than the concentrations in the newborns from non-smoking mothers.” 
1994 Field et al (1994).26 
Jul 1994 Field is a co-author on a paper which claims to have identified a new predisposing gene for 
head and neck cancers.27 
Jul 1994 Farmer(1994).28 
20-21 Sep 
1994 
SRG meeting, Hamburg.29 Notes that Farmer’s two PhD students will look at adducts and 
oxidative damage in smokers and non-smokers. 
Jan 1995 Field (1995).30 
Feb 1995 Summary of research projects funded by the SRG in 1995. 
24-25 Apr 
1995 
SRG meeting, Ǻrhus.31 
“Dr Cooper would be offered a donation to his research group in return for occasional 
presentations to the SRG on the state of current science in his field of expertise. The exact 
nature of the contract will be discussed with Dr Cooper but may provide a basis for similar 
arrangements with other scientists.” 
Also reports BAT’s receipt of the first year report from Farmer’s second PhD student. 
16 Mar 
1995 
Brennan et al (1995).32 Scientists at John Hopkins Medical Center report “molecular proof 
that smoking increases the rate of mutation” in the p53 gene”.33. 
The Tobacco Institute tells the Los Angeles Times “The Tobacco Institute does not have the 
sophisticated resources necessary to evaluate research on gene mutation theories.” 
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1995 Krawczak et al (1995). Vijay Kakkar and David Cooper, of the Thrombosis Research 
Institute, are co-authors.34 
“…we have demonstrated here that the bulk of the spectrum of somatic single basepair 
substitutions in the TP53 gene strongly resembles that of their germline counterparts seen in 
other human genes…it would appear that many TP53 mutations in the soma may have arisen 
directly or indirectly as a consequence of endogenous cellular mechanisms (perhaps 
including those involved in DNA repair and replication) rather than through the action of 
exogenous mutagens.” 




A BAT memo to SRG members35 outlines the findings in Brennan et al (1995).  
The memo claims that: “The mutations did not necessarily cause the cancer” and “Overall, in 
our opinion this study does not establish a causal link between smoking and cancer.”  
The memo gives one reference – Krawczak et al. (1995). 
Jul 1995 Poulsen & Loft (1995).The paper suggests that “oxygen species” can cause identical DNA 
damage to external chemicals (xenobiotics), such as those in tobacco smoke. 
Dec 1995 Farmer(1995).36 The paper emphasises that genetic damage (DNA adducts) could be formed 
by internal mechanisms (endogenous processes) rather than by exposure to cancer-causing 
chemicals.  
1996 Lawrence et al (1996).37 Farmer is a co-author. 
Describes a method for measuring adduct levels. Funding from the UK MRC and from the 
Commission of European Communities. 
May 1996 Farmer et al (1996).38 Finds “adduct levels in smokers were significantly higher than those in 
nonsmokers”. 
Jun 1996 Loft & Poulsen (1996).39 A review of cancer risk and oxidative DNA damage. 
The paper notes oxidative damage to DNA increases with age and that both ionizing radiation 
and smoking can increase damage rates. Suggests protective effects from eating Brussels 
sprouts, increasing vitamin C or eating a low-fat diet. 
Jul 1996 Farmer et al (1996).40 
Jul 1996 Lykkesfeldt et al (1996).41 Poulsen is a co-author. 
“These results…strongly suggest that the low ascorbic acid concentrations in [smokers’] 
plasma related to smoking per se” [rather than diet]. 
Acknowledges funding from BAT and the Danish Environmental Research Programme. 
Aug 1996 Poulsen et al (1996). “Oxidative stress to DNA points to a risk for the development of cancer 
and premature ageing from extreme exercise.” 
Jul 1998 Discussion Forum by Krawczak and Cooper is published in the journal Mutagenesis (of 
which James Parry is the editor).42 
Aug 1998 Philip Morris document re Parry’s “long-standing relationship” with them and his proposal 
for future work on (i) mutation spectra and (ii) genetic susceptibility.43 PM had previously 
funded Parry in 1996 to compare the effects of environmental hazards on the respiratory tract 
(including passive smoking, diesel fumes and urban pollution).44, 45 
Nov 1998 
 
Pfeifer et al (1998).46 Response to the Mutagenesis Discussion Forum. Describes Krawczak 
and Cooper’s main argument as “erroneous and misleading”. 
Mar 1999 Farmer & Shuker (1999).47 
Nov 2000 Paschke (2000) published in Mutagenesis.48 Claims no significant differences between p53 




Exchange of letters between Hainaut and Parry regarding the failure to declare tobacco 
funding of Paschke’s research institution [Personal communication]. 
Nov 2001 Hainaut et al’s reply to the Paschke’s article,49 together with a response from Paschke50, are 
published in Mutagenesis. Paschke now declares tobacco funding. 
Nov 2001 The last issue of Mutagenesis with Parry as editor in chief. 
The journal adopts a new policy on conflicts of interest.51 However, Parry remains on the 
editorial board and also becomes acting editor of the European Journal of Genetic and 
Molecular Toxicology.52 
Jun 2002 Lewis et al (2002).53 Parry is a co-author. The paper claims there is no difference in mtDNA 
mutations between smokers and non-smokers. 
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